A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001)

Inclusion Criteria

• •High-risk Acute Myeloid Leukemia (AML)
• •Have a diagnosis of AML according to the World Health Organization (WHO) criteria
• •Have an Eastern Cooperative Oncology Group (ECOG) performance status score ≤2
• •Have AML that is classified as high risk as defined by one of the following: ≥ 60 years of age who were not candidates for or have refused standard chemotherapy; ≥18 years of age with de novo or secondary AML who were not expected to benefit from standard remission-induction chemotherapy; or had relapsed/refractory AML after no more than 3 previous lines of chemotherapy.
• •High-risk Myelodysplastic Syndromes (MDS)
• •Have a diagnosis of myelodysplastic syndromes according to the World Health Organization (WHO) criteria
• •Have either an International Prognostic Scoring System (IPSS) score equivalent to intermediate-2 risk or higher, or a Revised International Prognostic Scoring System (IPSS-R) score equivalent to intermediate risk or higher.
• •Have MDS that is classified as high risk as defined by one of the following: participants who have failed first-line therapy; or treatment-related MDS, except if it is associated with favorable cytogenetics, and not a candidate for stem cell transplantation
• •Prior autologous stem cell transplant is allowed if a minimum of 3 months has elapsed from the time of transplant and the patient has recovered from transplant-associated toxicities
• •Prior allogeneic stem cell transplant is allowed, provided all of the following criteria are met: transplant was \>120 days prior to study enrollment; no immunosuppressive medications have been taken for at least 1 month; and no active graft versus host disease (GVHD), excluding Grade 1 skin GVHD
• •Has a life expectancy \>12 weeks